Kingfisher Capital’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $1.1M | Buy |
37,982
+71
| +0.2% | +$2.07K | 0.25% | 94 |
|
|
2024
Q2 | $1.06M | Buy |
37,911
+72
| +0.2% | +$1.98K | 0.25% | 90 |
|
|
2024
Q1 | $1.05M | Buy |
37,839
+109
| +0.3% | +$3.02K | 0.25% | 88 |
|
|
2023
Q4 | $1.09M | Buy |
37,730
+64
| +0.2% | +$1.94K | 0.28% | 86 |
|
|
2023
Q3 | $1.25M | Buy |
37,666
+55
| +0.1% | +$1.95K | 0.34% | 86 |
|
|
2023
Q2 | $1.38M | Buy |
37,611
+654
| +2% | +$25.5K | 0.36% | 80 |
|
|
2023
Q1 | $1.51M | Buy |
36,957
+46
| +0.1% | +$1.99K | 0.4% | 78 |
|
|
2022
Q4 | $1.89M | Sell |
36,911
-3,319
| -8% | -$159K | 0.5% | 69 |
|
|
2022
Q3 | $1.76M | Sell |
40,230
-121
| -0.3% | -$5.88K | 0.48% | 69 |
|
|
2022
Q2 | $2.12M | Buy |
40,351
+47
| +0.1% | +$2.4K | 0.61% | 59 |
|
|
2022
Q1 | $2.09M | Buy |
40,304
+145
| +0.4% | +$7.52K | 0.54% | 71 |
|
|
2021
Q4 | $2.37M | Buy |
40,159
+103
| +0.3% | +$5.1K | 0.55% | 77 |
|
|
2021
Q3 | $1.72M | Buy |
40,056
+294
| +0.7% | +$13K | 0.45% | 84 |
|
|
2021
Q2 | $1.56M | Sell |
39,762
-29
| -0.1% | -$1.13K | 0.4% | 93 |
|
|
2021
Q1 | $1.44M | Sell |
39,791
-182
| -0.5% | -$6.46K | 0.4% | 95 |
|
|
2020
Q4 | $1.47M | Sell |
39,973
-2,284
| -5% | -$83.8K | 0.45% | 90 |
|
|
2020
Q3 | $1.47M | Buy |
42,257
+3,928
| +10% | +$138K | 0.53% | 75 |
|
|
2020
Q2 | $1.19M | Buy |
38,329
+482
| +1% | +$16.4K | 0.53% | 78 |
|
|
2020
Q1 | $1.17M | Sell |
37,847
-1,921
| -5% | -$65.5K | 0.6% | 66 |
|
|
2019
Q4 | $1.48M | Sell |
39,768
-471
| -1% | -$16.8K | 0.69% | 49 |
|
|
2019
Q3 | $1.37M | Buy |
40,239
+174
| +0.4% | +$6.33K | 0.82% | 52 |
|
|
2019
Q2 | $1.65M | Sell |
40,065
-150
| -0.4% | -$5.96K | 1.02% | 38 |
|
|
2019
Q1 | $1.62M | Sell |
40,215
-763
| -2% | -$30.6K | 1.04% | 36 |
|
|
2018
Q4 | $1.7M | Buy |
40,978
+108
| +0.3% | +$4.48K | 1.21% | 26 |
|
|
2018
Q3 | $1.71M | Sell |
40,870
-3,725
| -8% | -$143K | 0.92% | 32 |
|
|
2018
Q2 | $1.53M | Buy |
44,595
+405
| +0.9% | +$13.8K | 0.97% | 34 |
|
|
2018
Q1 | $1.49M | Buy |
44,190
+2,985
| +7% | +$103K | 0.95% | 38 |
|
|
2017
Q4 | $1.42M | Sell |
41,205
-536
| -1% | -$18.3K | 0.9% | 42 |
|
|
2017
Q3 | $1.41M | Buy |
41,741
+384
| +0.9% | +$12.3K | 0.94% | 43 |
|
|
2017
Q2 | $1.32M | Buy |
41,357
+1,027
| +3% | +$32.4K | 0.89% | 46 |
|
|
2017
Q1 | $1.31M | Buy |
40,330
+3,703
| +10% | +$117K | 0.94% | 47 |
|
|
2016
Q4 | $1.13M | Sell |
36,627
-333
| -0.9% | -$10.2K | 0.85% | 52 |
|
|
2016
Q3 | $1.19M | Sell |
36,960
-769
| -2% | -$25.7K | 0.83% | 57 |
|
|
2016
Q2 | $1.26M | Buy |
37,729
+1,291
| +4% | +$41.2K | 0.83% | 55 |
|
|
2016
Q1 | $1.02M | Buy |
36,438
+3
| +0% | +$86 | 0.64% | 72 |
|
|
2015
Q4 | $1.12M | Sell |
36,435
-794
| -2% | -$25K | 0.66% | 71 |
|
|
2015
Q3 | $1.11M | Buy |
37,229
+519
| +1% | +$16.6K | 0.7% | 65 |
|
|
2015
Q2 | $1.17M | Buy |
36,710
+3
| +0% | +$98 | 0.67% | 72 |
|
|
2015
Q1 | $1.21M | Buy |
36,707
+3
| +0% | +$95 | 0.63% | 74 |
|
|
2014
Q4 | $1.08M | Sell |
36,704
-30
| -0.1% | -$860 | 0.56% | 85 |
|
|
2014
Q3 | $1.03M | Hold |
36,734
| – | – | 0.55% | 88 |
|
|
2014
Q2 | $1.03M | Sell |
36,734
-679
| -2% | -$19.4K | 0.54% | 92 |
|
|
2014
Q1 | $1.14M | Hold |
37,413
| – | – | 0.6% | 80 |
|
|
2013
Q4 | $1.09M | Sell |
37,413
-542
| -1% | -$15.8K | 0.59% | 75 |
|
|
2013
Q3 | $1.03M | Hold |
37,955
| – | – | 0.53% | 80 |
|
|
2013
Q2 | $1.01M | Buy |
+37,955
| New | +$1.05M | 0.55% | 75 |
|
Other funds holding PFE
Kingfisher Capital's PFE Position: Q3 2024 in Review
Kingfisher Capital increased its Pfizer (PFE) stake by 0.19% in Q3 2024, buying an estimated $2.07K and bringing the position to 37,982 shares worth $1.1M. The position accounts for 0.25% of the portfolio, ranked #94.
Kingfisher Capital first reported a position in PFE in Q2 2013 and has held it in 46 quarters since. The position peaked at $2.37M in Q4 2021. 2,909 funds tracked by Wall St. Rank hold PFE as of Q3 2024.
- Kingfisher Capital held 37,982 shares of Pfizer worth $1.1M as of Q3 2024.
- Kingfisher Capital bought 71 Pfizer shares in Q3 2024, an estimated $2.07K.
- Pfizer made up 0.25% of Kingfisher Capital's portfolio in Q3 2024, its #94 holding.
- Kingfisher Capital first reported a position in Pfizer in Q2 2013 and has held it in 46 quarters since.
- Kingfisher Capital's Pfizer position peaked at $2.37M in Q4 2021.
- 2,909 funds tracked by Wall St. Rank held Pfizer as of Q3 2024.
Based on Kingfisher Capital's 13F filing for Q3 2024, filed 14 Nov 2024.